Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996723 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00996723 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 25 participants.
The verdict
NCT00996723, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Interventions
- DRUG vandetanib and dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996723
The ClinicalTrials.gov registry entry for NCT00996723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vandetanib and dasatinib is the first listed.
NCT00996723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996723 about?
NCT00996723 is a clinical study titled "Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)". This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
What is the current status of trial NCT00996723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-10. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00996723?
The interventions under investigation include: vandetanib and dasatinib (DRUG).
Who is sponsoring clinical trial NCT00996723?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.